Abingdon Health PLC
Company Profile
Business description
Abingdon Health PLC develops, manufactures, and distributes diagnostic devices and provides regulatory consultancy to diagnostics businesses. It offers integrated lateral flow CRO/CDMO services covering feasibility, manufacturing, packaging, kitting, documentation, and commercial support. Segments include Contract Development (milestone-based third-party work, revenue over time by completion), Contract Manufacturing (development/manufacturing via daily consultancy, revenue at customer control point), Product Sales (AbC-19TM, Pocket Diagnostic, PCRD tests, research antibodies, carriage; point in time), and Regulatory Services (IVD/medical device compliance, revenue over time), with key revenue from Regulatory Services. It operates in the UK, USA/Canada, Europe, and rest of world.
Contact
York Biotech Campus
Sand Hutton
YorkYO41 1LZ
GBRT: +44 1904406050
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
30 June 2026
Employees
129
Stocks News & Analysis
stocks
Chart of the Week: Has gold reached bear market territory?
stocks
Fair value upgrade for this ASX income player
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,885.60 | 59.90 | 0.68% |
| CAC 40 | 7,974.82 | 157.88 | 2.02% |
| DAX 40 | 23,287.09 | 607.05 | 2.68% |
| Dow JONES (US) | 46,691.87 | 1,475.73 | 3.26% |
| FTSE 100 | 10,345.53 | 169.08 | 1.66% |
| HKSE | 25,294.03 | 505.89 | 2.04% |
| NASDAQ | 21,847.18 | 1,052.54 | 5.06% |
| Nikkei 225 | 53,739.68 | 2,675.96 | 5.24% |
| NZX 50 Index | 12,825.87 | 86.24 | -0.67% |
| S&P 500 | 6,581.00 | 52.48 | 0.80% |
| S&P/ASX 200 | 8,671.80 | 53.10 | 0.62% |
| SSE Composite Index | 3,948.55 | 56.69 | 1.46% |